Results 11 to 20 of about 4,521 (193)

Immune-Mediated Thrombocytopenia in an Ulcerative Colitis Patient After Initiating Filgotinib Treatment: A Case Report. [PDF]

Clin Case Rep
Moderate‐to‐severe ulcerative colitis can be effectively treated with JAK‐1 inhibition, but platelet counts should be closely monitored, especially in active disease.
van der Hoff MJ, El-Morabit F, Löwenberg M.   +2 more
europepmc   +3 more sources

Filgotinib in Active Noninfectious Uveitis [PDF]

JAMA Ophthalmology
ImportanceNoninfectious uveitis is a leading cause of visual impairment with an unmet need for additional treatment options.ObjectiveTo assess the efficacy and safety of filgotinib, a Janus kinase 1 (JAK1) preferential inhibitor, for the treatment of noninfectious uveitis.Design, Setting, and ParticipantsThe HUMBOLDT trial was a double-masked, placebo ...
Srivastava, Sunil K, Watkins, Timothy R, Nguyen, Quan Dong, Sharma, Sumit, Scales, David K, Dacey, Mark S, Shah, Rajiv E, Chu, David S, Grewal, Dilraj S, Faia, Lisa J, Suhler, Eric B, Genovese, Mark C, Guo, Ying, Barchuk, William T, Besuyen, Robin, Dick, Andrew D, Rosenbaum, James T   +16 more
openaire   +5 more sources

Multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in Behçet’s disease, idiopathic inflammatory myopathies and IgG4-related disease:DRIMID study protocol [PDF]

BMJ Open
Introduction:Research into novel therapies for rare, immune-mediated inflammatory diseases (IMIDs) faces significant challenges, including small patient populations, complex clinical trial design and difficulties in patient recruitment.
Checa, Cesar Magro, Geertsema-Hoeve, Bettina C., Goekoop, Robbert J., Present, Erik, Raaphorst, Joost, Rekers, Nicolle H., Tas, Sander W., Thurlings, Rogier M., van Laar, Jacob M., van Laar, Jan A.M., Welsing, Paco M.J.   +10 more
core   +3 more sources

Rheumatoid Arthritis Preceded by Interstitial Lung Disease Controlled by Long-Term Treatment With the Janus Kinase 1-Selective Inhibitor, Filgotinib: A Case Report. [PDF]

Respirol Case Rep
We present a case of ILD preceding RA onset. The disease activity of arthritis and ILD was controlled, and ILD was stabilised for 4 years with the JAK1 selective inhibitor, filgotinib. ABSTRACT We present a case of active interstitial lung disease (ILD) preceding the onset of rheumatoid arthritis (RA).
Sato T, Nakazawa S, Yamamoto S, Nagatani K, Sato K.   +4 more
europepmc   +2 more sources

Filgotinib Is an Effective and Safe Treatment Option for Difficult-To-Treat Ulcerative Colitis: Real-World Evidence of the Dutch Initiative on Crohn and Colitis (ICC) Registry. [PDF]

United European Gastroenterol J
ABSTRACT Background Filgotinib is a preferential Janus kinase 1 (JAK‐1) inhibitor registered for the treatment of ulcerative colitis (UC). Real‐world effectiveness of filgotinib, especially for difficult‐to‐treat (DTT, failure of ≥ 2 prior advanced therapies) patients, has been scarcely reported.
Naber MR, van der Meulen AE, Voorneveld PW, Veltkamp SHC, van Bodegraven AA, Bodelier A, Mujagic Z, Pierik M, Verleye LMM, Duijvestein M, Bouwknegt DG, Visschedijk MC, Srivastava N, West RL, Oldenburg B, Löwenberg M, van Schaik FDM, Dutch ICC Registry.   +17 more
europepmc   +2 more sources

Tofacitinib-Induced Weight Gain in Context: comment on the article by Wollenhaupt et al. [PDF]

ACR Open Rheumatol
ACR Open Rheumatology, Volume 8, Issue 2, February 2026.
Palmowski A, Buttgereit F, Simon D, Kleyer A, Drzeniek NM.   +4 more
europepmc   +2 more sources

Filgotinib Radiographic and Clinical Efficacy Versus Other JAK Inhibitors and Adalimumab in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate: A Systematic Review and Network Meta-Analysis. [PDF]

Rheumatol Ther
A Bayesian network meta-analysis was conducted to examine the radiographic and clinical efficacy of the Janus kinase (JAK) inhibitors tofacitinib, baricitinib, upadacitinib, and filgotinib and the biologic disease-modifying antirheumatic drug (bDMARD ...
Tanaka Y, Westhovens R, Sun H, Van der Donckt C, Zhong Y, Kaise T.   +5 more
europepmc   +2 more sources

Filgotinib in Rheumatoid Arthritis: A Profile of Its Use [PDF]

Clinical Drug Investigation, 2021
Filgotinib (Jyseleca®), an oral Janus kinase (JAK) inhibitor, is approved as monotherapy or in combination with methotrexate to treat moderate to severe active rheumatoid arthritis (RA) in adults who have an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).
Esther S. Kim, Susan J. Keam
openaire   +2 more sources

Emerging Topical and Systemic JAK Inhibitors in Dermatology [PDF]

, 2019
Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders.
Ghoreschi, Kamran, Meier, Katharina, Solimani, Farzan   +2 more
core   +1 more source

The impact of comorbidities on interleukin-17 inhibitor therapy in psoriatic arthritis: a Danish population-based cohort study [PDF]

, 2023
Objective To investigate the influence of comorbidities on treatment response, disease activity and persistence with first-line IL-17 inhibitor (IL-17i) treatment in patients with PsA.
Coates, Laura C, Egeberg, Alexander, Hansen, Rebekka L, Jørgensen, Tanja S, Kristensen, Lars Erik, Merola, Joseph Frank, Petersen, Magnus B   +6 more
core   +2 more sources